Patents by Inventor Jeffrey B. Ulmer

Jeffrey B. Ulmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS COV-2 SPIKE PROTEIN CONSTRUCT
    Publication number: 20230364219
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an antigen, in particular a Coronavirus antigen.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 16, 2023
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Dong YU, Giulietta MARUGGI, Jason W. WESTERBECK, Jeffrey B. ULMER, Jason P. LALIBERTE, Kate LUISI, Lin QU
  • Polynucleotide vaccine formulations
    Publication number: 20040242522
    Abstract: The present invention relates to a novel vaccine formulation comprising nucleic acid molecules and an mineral-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination which correlates to expression of one or more specific antigens encoded by the nucleic acid molecule.
    Type: Application
    Filed: January 26, 2004
    Publication date: December 2, 2004
    Inventors: David B. Volkin, Robert K. Evans, Jeffrey B. Ulmer, Michael J. Caulfield
  • Nucleic acid pharmaceuticals-influenza matrix
    Publication number: 20040087521
    Abstract: DNA constructs encoding influenza virus gene products, capable of being expressed upon direct introduction, via injection or otherwise, into animal tissues, are novel prophylactic pharmaceuticals which can provide immune protection against infection by homologous and heterologous strains of influenza virus.
    Type: Application
    Filed: April 16, 2001
    Publication date: May 6, 2004
    Applicant: Merck & Co., Inc.
    Inventors: John J. Donnelly, Varavani J. Dwarki, Margaret A. Liu, Donna L. Montgomery, Suezanne E. Parker, John W. Shiver, Jeffrey B. Ulmer
  • Polynucleotide vaccine formulations
    Publication number: 20020045594
    Abstract: The present invention relates to a novel vaccine formulation comprising nucleic acid molecules and an mineral-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination which correlates to expression of one or more specific antigens encoded by the nucleic acid molecule.
    Type: Application
    Filed: September 12, 2001
    Publication date: April 18, 2002
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Jeffrey B. Ulmer, Michael J. Caulfield